44 min listen
A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
ratings:
Length:
44 minutes
Released:
Oct 22, 2020
Format:
Podcast episode
Description
Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.
Released:
Oct 22, 2020
Format:
Podcast episode
Titles in the series (100)
Fast Money 10/30/17 by CNBC's "Fast Money"